Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The exon-3 deleted GH receptor (GHR(d3)) polymorphism is associated with an increased
growth response to recombinant human GH (rhGH) therapy in some, but not all, studies
in GH-deficient (GHD) and non-GHD children with short stature.